Straits Times Index
3,365.67 -12.62 (-0.37%) S&P 500
4,017.77 -52.79 (-1.30%) Dow
33,717.09 -260.99 (-0.77%) Nasdaq
11,393.81 -227.90 (-1.96%) BTC-USD
22,944.52 -171.13 (-0.74%) CMC Crypto 200
520.59 -17.28 (-3.21%)
AZN Oct 2023 65.000 put
| Previous close | 4.1500 |
| Open | 4.1500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 65.00 |
| Expiry date | 2023-10-20 |
| Day's range | 4.1500 - 4.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 54 |
- Zacks
Merck (MRK) to Report Q4 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings.
- Motley Fool
Could This Vaccine Become Sanofi's Latest Blockbuster?
Sanofi (NASDAQ: SNY) and AstraZeneca's (NASDAQ: AZN) application for the respiratory syncytial virus (RSV) vaccine candidate called nirsevimab was recently accepted for review by the U.S. Food and Drug Administration (FDA) as a protective option for all infants. Nirsevimab is known by the trade name Beyfortus in the European Union and the United Kingdom, and the FDA expects to make an approval decision on the RSV vaccine in the third quarter of this year.
- Financial Times
RQ Bio partners with AstraZeneca in Covid antibody fight
UK biotech RQ Bio is partnering with AstraZeneca as it races to keep its antibody to protect immunocompromised patients from Covid-19 up to date with the latest variants. The Anglo-Swedish pharmaceutical company recently launched a trial of a second generation of its Evusheld antibody, as the original appears unable to prevent infection from the XBB 1.5 variant. The antibodies are used to protect people who do not respond to vaccines, for example, if they have certain cancers.
